Want to see JP:4893 full AI Analyst Report?
Total Valuation
Noile-Immune Biotech Inc. has a market cap or net worth of ¥6.02B. The enterprise value is ¥1.54B.
Market Cap¥6.02B
Enterprise Value¥1.54B
Share Statistics
Noile-Immune Biotech Inc. has 43,276,764 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding43,276,764
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Noile-Immune Biotech Inc.’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -20.25%.
Return on Equity (ROE)-0.20
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)-20.25%
Return on Capital Employed (ROCE)-0.20
Revenue Per Employee217.39K
Profits Per Employee-34.50M
Employee Count23
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Noile-Immune Biotech Inc. is ―. Noile-Immune Biotech Inc.’s PEG ratio is 0.41.
PE Ratio―
PS Ratio1151.82
PB Ratio1.46
Price to Fair Value1.46
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio0.41
Income Statement
In the last 12 months, Noile-Immune Biotech Inc. had revenue of 5.00M and earned -793.54M in profits. Earnings per share was -18.33.
Revenue5.00M
Gross Profit5.00M
Operating Income-797.25M
Pretax Income-791.12M
Net Income-793.54M
EBITDA-797.25M
Earnings Per Share (EPS)-18.33
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Noile-Immune Biotech Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.41
52-Week Price Change-20.47%
50-Day Moving Average129.08
200-Day Moving Average146.63
Relative Strength Index (RSI)52.20
Average Volume (3m)85.17K
Important Dates
Noile-Immune Biotech Inc. upcoming earnings date is Aug 13, 2026, TBA (Confirmed).
Last Earnings DateMay 14, 2026
Next Earnings DateAug 13, 2026
Ex-Dividend Date―
Financial Position
Noile-Immune Biotech Inc. as a current ratio of 53.54, with Debt / Equity ratio of 0.00%
Current Ratio53.54
Quick Ratio53.51
Debt to Market Cap0.00
Net Debt to EBITDA4.91
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Noile-Immune Biotech Inc. has paid 2.42M in taxes.
Income Tax2.42M
Effective Tax Rate>-0.01
Enterprise Valuation
Noile-Immune Biotech Inc. EV to EBITDA ratio is -2.31, with an EV/FCF ratio of 0.00.
EV to Sales368.16
EV to EBITDA-2.31
EV to Free Cash Flow0.00
EV to Operating Cash Flow-2.45
Balance Sheet
Noile-Immune Biotech Inc. has ¥3.74B in cash and marketable securities with ¥0.00 in debt, giving a net cash position of ¥3.74B billion.
Cash & Marketable Securities¥3.74B
Total Debt¥0.00
Net Cash¥3.74B
Net Cash Per Share¥86.50
Tangible Book Value Per Share¥90.80
Margins
Gross margin is 73.66%, with operating margin of -15945.08%, and net profit margin of -15870.72%.
Gross Margin73.66%
Operating Margin-15945.08%
Pretax Margin-15822.32%
Net Profit Margin-15870.72%
EBITDA Margin-15945.08%
EBIT Margin-15945.08%
Analyst Forecast
The average price target for Noile-Immune Biotech Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-59.98%
EPS Growth Forecast18.23%